Spartanburg Regional Healthcare System, Spartanburg, SC 29303, USA.
Contraception. 2011 Oct;84(4):372-6. doi: 10.1016/j.contraception.2011.01.024. Epub 2011 Mar 15.
Studies show poor documentation of contraceptive counseling when prescribing women teratogenic medications, suggesting a missed opportunity for contraceptive education.
A retrospective chart review of selected Food and Drug Administration class D and X medications evaluated the office visit initiating this medication for documentation of either contraceptive counseling or provision. Following an educational intervention, another retrospective review was conducted to determine if the rate of counseling improved.
The initial rate of documented counseling was 46% and improved to 80% following the educational intervention (p=.0002), an improvement in both overall rate and that seen in the previous year.
This study is the first to document contraceptive counseling rates when providing teratogenic medications in a training setting. It illustrates a need for increased attentiveness in primary care training practices to the risks of teratogenic medications and the need for comprehensive contraceptive counseling. Simple interventions may improve this rate and decrease missed opportunities.
研究表明，在为女性开致畸药物时，避孕咨询的记录很差，这表明避孕教育的机会被错失了。
对选定的美国食品和药物管理局 D 类和 X 类药物进行回顾性图表审查，评估了启动该药物治疗的就诊记录，以确定是否有避孕咨询或提供避孕措施。在进行了教育干预之后，又进行了另一项回顾性审查，以确定咨询率是否有所提高。
初始记录的咨询率为 46%，在教育干预后提高到 80%（p=.0002），这一提高体现在总体率和前一年的记录率上。
这项研究首次记录了在培训环境中提供致畸药物时的避孕咨询率。它说明了在初级保健培训实践中需要更加关注致畸药物的风险，以及需要进行全面的避孕咨询。简单的干预措施可能会提高这一比率，并减少错失的机会。
